Navigation Links
Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Date:7/16/2009

SAN FRANCISCO, July 16 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed a private placement of shares of its common stock and warrants to purchase additional common stock for aggregate gross proceeds of approximately $3.4 million. Riverbank Capital Inc., a FINRA member broker dealer acted as the exclusive placement agent for the transaction.

"We are extremely pleased to have the completed this financing," said Joshua Kazam, Chief Executive Officer, "which we believe will provide us with sufficient capital to complete our Phase 2 clinical study of CD-NP in acute heart failure patients with mild to moderate renal insufficiency."

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under such act and applicable state securities laws or an applicable exemption from those registration requirements. Nile has agreed to file a registration statement covering the resale of the shares issued in the private placement, including the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas o
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
2. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
7. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
8. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
11. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...RNewswire/ - Aegera Therapeutics Inc. announced to...d Phase 2B study of AEG35156, a targeted antisense... oncology indications. ,, The study, entitled "...nked Inhibitor of Apoptosis (XIAP) Antisense AEG35... and Idarubicin in AML Following Failure of a Sing...
(Date:11/19/2009)...nd is honored by latest award for revolutionary he...PRWEB) November 16, 2009 -- Popular Science Magazi...ring aid from InSound Medical a winner of its cove...ategory.    Chosen from thousa...in the hearing canal for up to four months while p...
(Date:11/18/2009)...titute of Standards and Technology (NIST) has demo...or detecting and measuring elusive hazards such as...ge in food or pesticides distributed in soil by wi...e than conventional techniques for detecting trace...lecules, having distinct electrically positive and...
(Date:11/18/2009)...ity Belfast are developing new sensors to detect c...n the fight against the threat of terrorist attack...wipe, an individual or crime scene to gather a sam...t that can detect the presence of chemicals within... to be made in response to terrorist threats. , ...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3Prototype NIST method detects and measures elusive hazards 2New technology detects chemical weapons in seconds 2
...uct line in the United S...agnostics and Response,Biomedical have entered int...e first line of cardiovascular tests for Response ...tform, the RAMP(R) 200 (Rapid Analyte Measurement ...eady used in laboratories worldwide for,West Nile ...
...Newswire-FirstCall/ --,Kiwa Bio-Tech Products Grou... that Kiwa Bio-Tech Products (Shandong) Co., Ltd. ...totaling RMB 150 million (over US$21,million) with...Co., Ltd.,and other distributors. Delivery of prod...m August 2008 through March 2009., Prior to enter...
...axy,Pharmaceuticals Inc. (RPI), a wholly owned sub...gaon, India announced today that under an,agreemen... an authorized,generic of Omeprazole 40 mg Capsule...is indicated for the treatment of acid-related dis... syndrome. The most common,side effects of Prilose...
Other Biology Technology:Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests 2Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests 3Kiwa Bio-Tech Signs RMB 150 Million (US$21+ million) Fertilizer Contract 2Kiwa Bio-Tech Signs RMB 150 Million (US$21+ million) Fertilizer Contract 3Ranbaxy Launches Omeprazole 40 mg Capsules 2
(Date:11/20/2009)...RBOR, Mich.---We,ve all read studies about the hea...ing is true at the molecular level, where amino ac... damage when single than when paired up with other... of Michigan, along with colleagues in Belgium, ha...ts single cysteines. The research appears in the N...
(Date:11/20/2009)...key question in the origin of biological molecules...billions of years ago from simple precursors. Now,...ers in Italy have reconstructed one of the earlies...f RNA from individual subunits using nothing but w...was one of the first biological molecules present,...
(Date:11/20/2009)... release is available in German . , In the ...nvestigation , Dr. Stefanie Eyerich and Dr. Kilian...ial College London and Istituto Dermopatico dell,I...scovery. It represents a milestone on the way to d...kin diseases such as psoriasis and allergic reacti...
Breaking Biology News(10 mins):Saving the single cysteine: New antioxidant system found 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Gen Probe Reports Financial Results for Second Quarter 2009 53283 1Gen Probe Reports Financial Results for Second Quarter 2009 53283 2Gen Probe Reports Financial Results for Second Quarter 2009 53283 3Gen Probe Reports Financial Results for Second Quarter 2009 53283 4Gen Probe Reports Financial Results for Second Quarter 2009 53283 5Gen Probe Reports Financial Results for Second Quarter 2009 53283 6Gen Probe Reports Financial Results for Second Quarter 2009 53283 7Gen Probe Reports Financial Results for Second Quarter 2009 53283 8Gen Probe Reports Financial Results for Second Quarter 2009 53283 9Gen Probe Reports Financial Results for Second Quarter 2009 53283 10Gen Probe Reports Financial Results for Second Quarter 2009 53283 11Gen Probe Reports Financial Results for Second Quarter 2009 53283 12Gen Probe Reports Financial Results for Second Quarter 2009 53283 13Gen Probe Reports Financial Results for Second Quarter 2009 53283 14Gen Probe Reports Financial Results for Second Quarter 2009 53283 15Gen Probe Reports Financial Results for Second Quarter 2009 53283 16Gen Probe Reports Financial Results for Second Quarter 2009 53283 17Gen Probe Reports Financial Results for Second Quarter 2009 53283 18Gen Probe Reports Financial Results for Second Quarter 2009 53283 19Gen Probe Reports Financial Results for Second Quarter 2009 53283 20Gen Probe Reports Financial Results for Second Quarter 2009 53283 21Gen Probe Reports Financial Results for Second Quarter 2009 53283 22Millions of Pennsylvanians Could Lose Private Insurance Study Shows 53279 1Millions of Pennsylvanians Could Lose Private Insurance Study Shows 53279 2Muscle Density Linked to Disability 53275 1Muscle Density Linked to Disability 53275 2
...GAN The 102nd Annual International Meeting of the...ngineers will convene June 29 - July 2, at the Rho...n Providence, RI. , More than 1100 technical pre...soil and water quality, pesticide application tech... renewable energy, food safety, and more. , Speci...
...available in French and Spanish . , Montreal,...are joining forces to protect and conserve the Mon... America,s shared environment. , Although the mon...er of extinction, its unique multigenerational mig...angered biological phenomenon due to threats to th...
... flies has shown that enhancing the production of ...on of plaques and neuron death associated with Alz...fespan. , The buildup of amyloid-beta protein pl...eimer,s, and one that is believed to contribute to...ew up and clear these plaques, and deficiencies in...
Other Biology News:2008 ASABE Annual International Meeting 2Continental plan to protect the monarch's migratory journey 2
Peptide Antibody from Proteintech Group, Inc.
...r system for large format and medium throughput 2-...t gels (26 x 20 cm) simultaneously.Use with 18- or...mm or 1.5-mm pre-assembled hinged gel cassettes.In...uilt-in ceramic heat exchanger and buffer circulat...
ELF® 97 Immunohistochemistry Kit from Molecular Probes (Invitrogen)
Bovine Albumin from Bovine Serum, BODIPY FL conjugated/tagged from Molecular Probes (Invitrogen)
Biology Products: